Moreover, resistance mutations were only identified in a few genes (BTK, PLC2G, and BCL2), suggesting that a targeted mutation panel might be a more cost-effective approach that would achieve the same results as CGP when the goal is to identify variants that confer therapy resistance in CLL. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.